{"analyses":[{"ciLowerLimit":"-11.3","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"38.3","estimateComment":"Risk difference is estimated probability of survival in r+C+G minus the estimated probability of survival in C+G group.","groupDescription":"Percentage proportion calculated by Kaplan-Meier method.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.2856","pValueComment":"2-sided","paramType":"Risk Difference (RD)","paramValue":"13.5","statisticalComment":"Variance calculated by Greenwood's method.","statisticalMethod":"Chi-squared"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"16.8","upperLimit":"50.9","value":"33.3"},{"groupId":"OG001","lowerLimit":"6.3","upperLimit":"38.9","value":"19.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"22"}],"units":"Participants"}],"description":"Proportion surviving at 30 months","dispersionType":"95% Confidence Interval","groups":[{"description":"rAd-IFN (Study Day 1) + celecoxib (Study Days 1 to 14) + gemcitabine (Study Days 14 and 21 \\[i.e., Days 1 and 8 of the first gemcitabine treatment cycle\\], gemcitabine will be administered on a 21-day cycle, unless the cycle is modified due to toxicity/delay, and repeated every 3 weeks until disease progression/early termination \\[ET\\]\n\nrAd-IFN: Adenovirus-Delivered Interferon Alpha-2b\n\nCelecoxib Oral Product: 400 mg twice daily\n\nGemcitabine: 1250 mg/m2 administered intravenously on Days 1 and 8 of a 21-day cycle and continued every 3 weeks until disease progression/ early termination","id":"OG000","title":"Treatment Group"},{"description":"Celecoxib (Study Days 1 to 14) + gemcitabine (Study Days 14 and 21 \\[i.e., Days 1 and 8 of the first gemcitabine treatment cycle\\], gemcitabine will be administered on a 21-day cycle, unless the cycle is modified due to toxicity/delay, and repeated every 3 weeks until disease progression/ET.\n\nCelecoxib Oral Product: 400 mg twice daily\n\nGemcitabine: 1250 mg/m2 administered intravenously on Days 1 and 8 of a 21-day cycle and continued every 3 weeks until disease progression/ early termination","id":"OG001","title":"Control Group"}],"paramType":"NUMBER","populationDescription":"The Full Analysis Set, which comprised all patients who were appropriately randomized into the study and who received at least 1 dose of study drug (rAd-IFN, celecoxib, or gemcitabine).","reportingStatus":"POSTED","timeFrame":"30 months","title":"Survival Rate at 30 Months","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"Percentage of survivors"}